These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38430106)

  • 21. Immunoglobulin E and bullous pemphigoid.
    Cozzani E; Gasparini G; Di Zenzo G; Parodi A
    Eur J Dermatol; 2018 Aug; 28(4):440-448. PubMed ID: 30325326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical effect of omalizumab as an adjuvant treatment to rituximab in patient with refractory bullous pemphigoid.
    Kwon IJ; Kim T; Yoo DS; Min S; Kim SC; Kim JH
    J Dermatol; 2023 May; 50(5):705-709. PubMed ID: 36514846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IgE autoantibodies in bullous pemphigoid: supporting role, or leading player?
    Ujiie H
    J Dermatol Sci; 2015 Apr; 78(1):5-10. PubMed ID: 25797172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
    van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
    JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies.
    Barrios DM; Phillips GS; Geisler AN; Trelles SR; Markova A; Noor SJ; Quigley EA; Haliasos HC; Moy AP; Schram AM; Bromberg J; Funt SA; Voss MH; Drilon A; Hellmann MD; Comen EA; Narala S; Patel AB; Wetzel M; Jung JY; Leung DYM; Lacouture ME
    Ann Oncol; 2021 Jun; 32(6):736-745. PubMed ID: 33667669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting type 2 inflammation in bullous pemphigoid: current and emerging therapeutic approaches.
    Toh WH; Lee HE; Chen CB
    Front Med (Lausanne); 2023; 10():1196946. PubMed ID: 37614956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete Remission in a Patient with Treatment Refractory Bullous Pemphigoid after a Single Dose of Omalizumab.
    Sinha S; Agrawal D; Sardana K; Kulhari A; Malhotra P
    Indian Dermatol Online J; 2020; 11(4):607-611. PubMed ID: 32832453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bullous Diseases.
    Corbaux C; Joly P
    Curr Probl Dermatol; 2018; 53():64-69. PubMed ID: 29131038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dramatic improvement of bullous pemphigoid with omalizumab in an elderly patient.
    Navarro-Triviño FJ; Llamas-Molina JM; Ayen-Rodriguez A; Cancela-Díez B; Ruiz-Villaverde R
    Eur J Hosp Pharm; 2021 Nov; 28(6):350-352. PubMed ID: 32920533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful Omalizumab Therapy for Bullous Pemphigoid Despite Transient Reaction.
    Ewy S; Pham H; Quan K; Su B; Tachdjian R
    J Drugs Dermatol; 2019 Sep; 18(9):947-949. PubMed ID: 31524994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
    Atzori L; Deidda S; Aste N
    G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bullous Pemphigoid Masquerading as Erythema Annulare Centrifugum.
    Yu-Yang S; Chu-Sung Hu S; Yiao-Lin S
    Acta Dermatovenerol Croat; 2017 Oct; 25(3):255-256. PubMed ID: 29252183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid.
    Chen F; Wang Y; Chen X; Yang N; Li L
    Ann Med; 2023 Dec; 55(1):1156-1170. PubMed ID: 36999962
    [No Abstract]   [Full Text] [Related]  

  • 34. Increasing evidence for omalizumab in the treatment of bullous pemphigoid.
    Lonowski S; Sachsman S; Patel N; Truong A; Holland V
    JAAD Case Rep; 2020 Mar; 6(3):228-233. PubMed ID: 32140524
    [No Abstract]   [Full Text] [Related]  

  • 35. Omalizumab Treatment for Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis.
    Emiralioglu N; Dogru D; Tugcu GD; Yalcin E; Kiper N; Ozcelik U
    Ann Pharmacother; 2016 Mar; 50(3):188-93. PubMed ID: 26699090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).
    Borradori L; Van Beek N; Feliciani C; Tedbirt B; Antiga E; Bergman R; Böckle BC; Caproni M; Caux F; Chandran NS; Cianchini G; Daneshpazhooh M; De D; Didona D; Di Zenzo GM; Dmochowski M; Drenovska K; Ehrchen J; Goebeler M; Groves R; Günther C; Horvath B; Hertl M; Hofmann S; Ioannides D; Itzlinger-Monshi B; Jedličková J; Kowalewski C; Kridin K; Lim YL; Marinovic B; Marzano AV; Mascaro JM; Meijer JM; Murrell D; Patsatsi K; Pincelli C; Prost C; Rappersberger K; Sárdy M; Setterfield J; Shahid M; Sprecher E; Tasanen K; Uzun S; Vassileva S; Vestergaard K; Vorobyev A; Vujic I; Wang G; Wozniak K; Yayli S; Zambruno G; Zillikens D; Schmidt E; Joly P
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1689-1704. PubMed ID: 35766904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
    Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
    Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200.
    Yalcin AD; Genc GE; Celik B; Gumuslu S
    Clin Lab; 2014; 60(3):523-4. PubMed ID: 24697134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid.
    Messingham KN; Crowe TP; Fairley JA
    Front Immunol; 2019; 10():2331. PubMed ID: 31636640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.